Synapse - Gary Schwartz

Phase I trial of the cyclin-dependent kinase inhibitor and protein kinase C inhibitor 7-hydroxystaurosporine in combination with fluorouracil in patients with advanced solid tumors

Journal Article

Kortmansky, J.; Shah, M. A.; Kaubisch, A.; Weyerbacher, A.; Yi, S.; Tong, W.; Sowers, R.; Gonen, M.; O'reilly, E.; Kemeny, N.; more...
Journal of Clinical Oncology (2005)

Fulltext@MSK | Save

Phase II study of doxorubicin and bevacizumab for patients with metastatic soft-tissue sarcomas

Journal Article

D'adamo, D. R.; Anderson, S. E.; Albritton, K.; Yamada, J.; Riedel, E.; Scheu, K.; Schwartz, G. K.; Chen, H.; Maki, R. G.
Journal of Clinical Oncology (2005)

Fulltext@MSK | Save

Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry

Journal Article

Chung, K. Y.; Shia, J.; Kemeny, N. E.; Shah, M.; Schwartz, G. K.; Tse, A.; Hamilton, A.; Pan, D.; Schrag, D.; Schwartz, L.; more...
Journal of Clinical Oncology (2005)

Fulltext@MSK | Save

A phase II study of intravenous exatecan administered daily for 5 days, every 3 weeks to patients with biliary tract cancers

Journal Article

Abou-Alfa, G. K.; Rowinsky, E. K.; Patt, Y. Z.; Schwartz, G. K.; Kelsen, D. P.; Sharma, S.; Siegel, E.; Becerra, C. R.; Eckhardt, S. G.; Feit, K.; more...
American Journal of Clinical Oncology (2005)

Fulltext@MSK | Save

CHIR 124, a novel and potent inhibitor of chk1, potentiates the anti-tumor activity of topoisomerase I poisons in vitro and in vivo

Meeting Abstract

Tse, A. N.; Embry, M.; Aardalen, K.; Shao, Y.; Rendahl, K.; Menezes, D.; Hibner, B.; Gesner, T.; Schwartz, G.
Cancer Research (2004)

Fulltext@MSK | Save

p53 is a critical element for response to sequential SN-38 (SN) and flavopiridol (F): In vitro studies and clinical correlates

Meeting Abstract

Motwani, M. V.; Shah, M. A.; Schwartz, G. K.
Cancer Research (2004)

Fulltext@MSK | Save